Viking’s Phase IIb NASH Data Provide Across-The-Board Success

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Competing with Madrigal in the THRβ agonist class in non-alcoholic steatohepatitis, Viking’s VK2809 reports stronger efficacy and better safety and tolerability than resmetirom at that stage.

Archer
Viking's NASH candidate hits multiple targets in Phase IIb study • Source: Shutterstock

Madrigal Pharmaceuticals, Inc. will presumably hold a significant lead on the market for its THRβ agonist resmetirom (MDGL-3196), which it plans to file for US approval in non-alcoholic steatohepatitis this quarter, but Phase IIb data reported on 16 May for Viking Therapeutics, Inc.’s THRβ agonist, VK2809, led to analysts calling the drug a best-in-class candidate for NASH. VK2809 hit its primary endpoint of reduction from baseline in liver fat content (LFC) at 12 weeks compared to placebo in the VOYAGE study.

Madrigal is running second to Intercept Pharmaceuticals, Inc. in the race to bring the first NASH drug therapy to...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D